Table 2. Response rate according to histology (A) and regimen of first-line chemotherapy (B).
|
(2A)
| |||
|---|---|---|---|
| Response | Mucinous (n=49) | Non-mucinous (n=206) | |
| Complete response | 0 | 14 (6.8%) | |
| Partial response | 9 (18.4%) | 87 (42.2%) | |
| Overall response rate, % (95% CI) | 18.4 (7.5–29.2) | 49.0 (42.2–55.8) | |
| Stable disease | 18 (36.7%) | 57 (27.7%) | |
| Progressive disease | 22 (44.9%) | 48 (23.3%) | |
|
(2B)
| |||
| Chemotherapy regimen | N | Mucinous responders a | Non-mucinous responders a |
| OXA-based | 169 | 6/34 (17.6%) | 57/135 (42.2%) |
| IRI-based | 65 | 1/9 (11.1%) | 32/56 (57.1%) |
| OXA/IRI-based | 21 | 2/6 (33.3%) | 12/15 (80.0%) |
CI=confidence interval; IRI=iriotecan; OXA=oxaliplatin.
a
Responders=complete plus partial responses according to the RECIST.